Translational Assess. of Kinase Targets in Lung Cancer

翻译评估。

• 批准号: 7085423
• 负责人: AFSHIN DOWLATI
• 金额: $ 13.45万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7085423
• 关键词: JAK kinase; acute phase protein; antineoplastics; biological signal transduction; cell growth regulation; cell proliferation; clinical research; clinical trial phase I; clinical trial phase II; drug design /synthesis /production; drug screening /evaluation; epidermal growth factor; growth factor receptors; human subject; laboratory mouse; lung neoplasms; mitogen activated protein kinase; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; nonsmall cell lung cancer; patient oriented research; phosphatidylinositol 3 kinase; phosphorylation; protein tyrosine kinase; receptor expression

DESCRIPTION (provided by applicant): The overall goal of this grant application is to support the development of a mentored-career that focuses on building a foundation of translational/clinical mechanism-based anticancer drug development. This includes understanding the concept of target validation in the laboratory and drug development in the clinic with emphasis on the use of laboratory-based correlative studies during early phase clinical trials. To achieve this goal, we will focus on the effects of agents targeting the ErbB receptor family on receptor phosphorylation and the activation of downstream PI3K/AKT, MAPK, and JAK/STAT pathways in patients with solid tumors with special emphasis on non-small cell lung cancer (NSCLC). Aim 1: We will determine the prognostic value of EGFR phosphorylation and phosphorylation of downstream effector proteins (p-MAPK, p-AKT, p-STAT3) in comparison to total expression of these proteins in untreated NSCLC. This will be done by performing immunohistochemical analysis of 200 surgically resected NSCLC patients for both total and phosphorylated EGFR, MAPK, AKT and STAT3. Aim 2: To establish whether inhibition of both EGFR and downstream target STAT-3 have additive anti-proliferative activity in vivo. We have established in vitro that the combination of agents targeting EGFR and the JAK/STAT pathways in A431 cells have superior growth inhibitory effects in combination as opposed to single agents. Completion of this aim will demonstrate if strategies to block EGFR and JAK/STAT pathways are more effective than single agents in tumor xenograft models overexpressing EGFR. Aim 3: Determine in a phase I trial if treatment with GW572016, an agent targeting ErbB receptors, decreases EGFPJErbB2 phosphorylation and reduces activation of downstream effector proteins (AKT, MAPK, STAT3) within tumor tissue. Sequential tumor biopsies will be obtained. This trial will establish if this small molecule dual inhibitor of EGFR/erb-B2 effects its target receptor activation and downstream effector proteins in human tumor tissue and it will also establish the optimal biological dose (minimal dose required to effect receptor activation) in patients with advanced solid tumors. Aim 4:To determine the efficacy (response rate) of GW572016 (dual EGFPJErbB2 inhibitor) in NSCLC during a phase II clinical trial. Based on our preclinical data targeting EGFR and ErbB2 results in superior anti-tumor activity as compared to EGFR blockade alone.

描述（由申请人提供）：本资助申请的总体目标是支持一个指导职业的发展，重点是建立基于转化/临床机制的抗癌药物开发的基础。这包括理解实验室目标验证和临床药物开发的概念，重点是在早期临床试验期间使用基于实验室的相关研究。为了实现这一目标，我们将重点关注靶向ErbB受体家族的药物对实体瘤患者（特别是非小细胞肺癌（NSCLC）患者）受体磷酸化和下游PI 3 K/AKT、MAPK和JAK/STAT通路激活的影响。目标1：我们将确定EGFR磷酸化和下游效应蛋白（p-MAPK、p-AKT、p-STAT 3）磷酸化与未治疗NSCLC中这些蛋白的总表达相比的预后价值。这将通过对200例手术切除的NSCLC患者进行总EGFR和磷酸化EGFR、MAPK、AKT和STAT 3的免疫组织化学分析来完成。目的2：确定抑制EGFR和下游靶标STAT-3是否具有体内相加的抗增殖活性。我们已经在体外证实，靶向A431细胞中EGFR和JAK/STAT途径的药物组合与单一药物相比具有上级生长抑制作用。这一目标的完成将证明阻断EGFR和JAK/STAT通路的策略是否比过表达EGFR的肿瘤异种移植模型中的单一药物更有效。目标三：在I期试验中确定GW 572016（一种靶向ErbB受体的药物）治疗是否会减少EGFPJErbB 2磷酸化并减少肿瘤组织内下游效应蛋白（AKT、MAPK、STAT 3）的激活。将获得连续的肿瘤活检。本试验将确定这种EGFR/erb-B2的小分子双重抑制剂是否影响其在人肿瘤组织中的靶受体活化和下游效应蛋白，还将确定晚期实体瘤患者的最佳生物剂量（影响受体活化所需的最小剂量）。目的4：在II期临床试验期间确定GW 572016（双重EGFP/ErbB 2抑制剂）在NSCLC中的疗效（响应率）。基于我们的临床前数据，靶向EGFR和ErbB 2的抗肿瘤活性上级单独的EGFR阻断剂。